These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 19008289)

  • 21. Evaluation of 99mTc-succimer dosing in pediatric patients.
    Galbraith W; Nguyen A; Harrison DL; Chen X; Talley K
    J Nucl Med Technol; 2013 Jun; 41(2):81-4. PubMed ID: 23608072
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationship of decreased chemotaxis of technetium-99m-HMPAO-labeled lymphocytes to apoptosis.
    Van de Wiele C; Philippé J; Van Haelst JP; Van Damme J; Thierens H; Leroux-Roels GE; Dierckx RA
    J Nucl Med; 1997 Sep; 38(9):1417-21. PubMed ID: 9293800
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Simultaneous acquisition of (99m)Tc- and (123)I-labeled radiotracers using a preclinical SPECT scanner with CZT detectors.
    Kobayashi M; Matsunari I; Nishi K; Mizutani A; Miyazaki Y; Ogai K; Sugama J; Shiba K; Kawai K; Kinuya S
    Ann Nucl Med; 2016 May; 30(4):263-71. PubMed ID: 26747655
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A trial study of leukocyte labeling with stabilized Tc-99m D,L-HMPAO by methylene blue and sodium phosphate buffer.
    Kao CH; Huang WT; Wey SP; Changlai SP; Liao KK; Tsai CS
    Appl Radiat Isot; 1999 Mar; 50(3):513-9. PubMed ID: 10070711
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New synthesis route of active substance d,l-HMPAO for preparation Technetium Tc99m Exametazime.
    Pijarowska-Kruszyna J; Karczmarczyk U; Jaroń AW; Laszuk E; Radzik M; Garnuszek P; Mikołajczak R
    Nucl Med Rev Cent East Eur; 2017; 20(2):88-94. PubMed ID: 28555448
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of selected preparation variables on the radiochemical purity of 99mTc-sestamibi.
    Norenberg JP; Vaidya MP; Hladik WB; Pathak DR; Born JL; Anderson TL; Carroll TR
    J Nucl Med Technol; 2005 Mar; 33(1):34-41. PubMed ID: 15731019
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stabilization of Tc-99m D,L-HMPAO preparations as a leucocyte labelling agent.
    Kao CH; Huang WT; Tsai CS
    Appl Radiat Isot; 1998 Dec; 49(12):1595-8. PubMed ID: 9745694
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Technetium-99m-hexamethylpropylene amine oxime lung scintigraphy findings in patients with Behçet's disease.
    Gumuser G; Pirildar T; Tarhan S; Batok D; Ruksen E; Sakar A; Sayit E
    Nucl Med Commun; 2011 May; 32(5):363-8. PubMed ID: 21394049
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biodistribution study and identification of inflammatory sites using nanocapsules labeled with (99m)Tc-HMPAO.
    Pereira MA; Mosqueira VC; Carmo VA; Ferrari CS; Reis EC; Ramaldes GA; Cardoso VN
    Nucl Med Commun; 2009 Sep; 30(9):749-55. PubMed ID: 19593235
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stability of bortezomib 1-mg/mL solution in plastic syringe and glass vial.
    André P; Cisternino S; Chiadmi F; Toledano A; Schlatter J; Fain O; Fontan JE
    Ann Pharmacother; 2005 Sep; 39(9):1462-6. PubMed ID: 15985470
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-Xa stability of diluted enoxaparin for use in pediatrics.
    Dager WE; Gosselin RC; King JH; Christensen CL; Owings JT; Larkin EC
    Ann Pharmacother; 2004 Apr; 38(4):569-73. PubMed ID: 14982984
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Labeling of mixed leukocytes with (99m)Tc-HMPAO causes severe chromosomal aberrations in lymphocytes.
    Ak I; Vardereli E; Durak B; Gülbaş Z; Basaran N; Stokkel MP; Pauwels EK
    J Nucl Med; 2002 Feb; 43(2):203-6. PubMed ID: 11850485
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Radiochemical purity and stability of Tc-99m-pyrophosphate].
    Vucina J
    Med Pregl; 2000; 53(9-10):502-5. PubMed ID: 11320732
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stabilisation of high-activity 99mTc-d,l-HMPAO preparations with cobalt chloride and their biological behaviour.
    Mang'era KO; Vanbilloen HP; Schiepers CW; Verbruggen AM
    Eur J Nucl Med; 1995 Oct; 22(10):1163-72. PubMed ID: 8542901
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biodistribution and radiation dosimetry of stabilized 99mTc-exametazine-labeled leukocytes in normal subjects.
    Robins PD; Salazar I; Forstrom LA; Mullan BP; Hung JC
    J Nucl Med; 2000 May; 41(5):934-40. PubMed ID: 10809211
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lymphocyte labeling with technetium-99m-HMPAO: a radiotoxicity study using the micronucleus assay.
    Thierens HM; Vral AM; Van Haelst JP; Van de Wiele C; Schelstraete KH; de Ridder LI
    J Nucl Med; 1992 Jun; 33(6):1167-74. PubMed ID: 1597733
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Time dependence of iprofenin-labeling with technetium Tc 99m.
    Ponto JA; Ponto LL
    Am J Hosp Pharm; 1981 Dec; 38(12):1939-41. PubMed ID: 7325178
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of pertechnetate source and age on the radiochemical purity of technetium Tc 99m exametazime.
    Ponto JA
    Am J Hosp Pharm; 1990 Nov; 47(11):2511-3. PubMed ID: 2177584
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of four 1-mL syringes for administering first-pass radionuclide angiography doses.
    McGough CG; Huang DC; Hung JC
    J Nucl Med Technol; 1999 Sep; 27(3):227-9. PubMed ID: 10512480
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of Tetrofosmin Cold Kit Fractionation Using Alternative New Method of Quality Control for Testing Radiochemical Purity.
    Bhatia N; Vatsa R; Dhingra VK; Dhawan DK; Chadha VD
    World J Nucl Med; 2022 Dec; 21(4):314-319. PubMed ID: 36398310
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.